Trimethylsulfoxonium Bromide Cas:25596-24-1

We are Trimethylsulfoxonium Bromide CAS:25596-24-1 manufacturer and supplier in China, Pls send inquiry of to of visit our official website should you have any interests

Trimethylsulfoxonium Bromide

Trimethylsulfoxonium Bromide

molecular formula: C3H9BrOS
Molecular weight: 173.07200
Physical Properties:
Density: 1.440 (estimate)
Appearance: white fine powder
Purity: 99.0%

Mainly used for the synthesis of fluconazole. Strong base treatment can generate ylide. ylide can react with the carbonyl of ketone and aldehyde to form epoxide; it can also preferentially react with the double bond of α.β-unsaturated ester to generate cyclic lactone .
Package and Storage:
25KG/cardboard drum can be split

Market News:Prime Minister Naftali Bennett, launching the campaign, said President Isaac Herzog would be the first to receive the booster, on Friday. methyl 2-(4-cyanobutoxy)benzoate manufacturer.Inspired by the spirit of Start with Integrity, Succeed through Action,” Innovent’s mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit 5-(3-chloro-4-fluorophenyl)-5-oxopentanoic acid supplier.Walmsley’s background in consumer health—and lack of prior experience in pharma—has reportedly been targeted by Elliott in the investment firm’s secret push for a new boss at GSK. methyl 2-(benzhydrylideneamino)prop-2-enoate producer.

Related Products
Product Name
CAS:1760-24-3 WACKER GENIOSIL GF 91 View Details
Thiosemicarbazide View Details
BASF light stabilizer Tinuvin B75 View Details
6-Ethyl-3-oxa-6-azaoctanol manufacturer 2′-Deoxy-2′-fluorocytidine manufacturer 3-Bromobenzaldehyde manufacturer CAS:3055-93-4 ; 9002-92-0 ; 68439-50-9 Brij 30 manufacturer 2-Bromo-3-(Trifluoromethyl)Aniline manufacturer